This article is more than 5 years old. Information may no longer be current.
VIDEO: Data give ‘pause’ about widespread use of CAR T-cell therapy for ALL
SAN DIEGO — Ryan D. Cassaday, MD, of Seattle Cancer Care Alliance spoke with HemOnc Today at the ASH Annual Meeting and Exposition about trial data related to the treatment of chimeric antigen receptor T-cell therapy in patients with acute lymphocytic leukemia.
CAR T-cell therapy has generated high response rates in high-risk patients, however, the toxicity profile of this treatment approach continues to be a concern, Cassaday said.
“I think this causes us to take a bit of a pause about how this therapy could potentially be applied outside the context of highly-selected patients enrolled in clinical trials,” Cassaday said. – by Kristie L. Kahl
Disclosure: Cassaday reports research support from Seattle Genetics.